Axim Biotechnologies Inc (AXIM)

[Devolution]

Based on the latest Press Release of February 15:

https://www.globenewswire.com/news-release/2022/02/15/2385339/33692/en/AXIM-Biotech-Announces-New-Milestones-in-Preparation-of-Dry-Eye-Disease-Diagnostics-Launch.html

I would like to believe that we will see the onset of revenues from the DED test kits in the 1st quarter 10-Q, certainly by the 2nd quarter.

Your summary as follows:

A quick at home test of your own level of neutralizing antibodies would help both you and your physician make decisions that are instrumental in minimizing future morbidity and mortality for the patient and the related costs to society.

precisely expresses how most of us feel.

Immunopass appears to be a "no-brainer" when it comes to enabling the individual to make his/her own health decisions.

Immunopass is inexpensive, easy to use, over the counter, immediate results, highly accurate, etc.

I personally believe it is a combination of abuse of political powers by those in charge and corruption within the FDA that are the major snags, but it does look like the politics (control of the population through mask mandates and vaccine mandates, etc.) are quickly changing (failing), and the corruption within the FDA was recently exposed by Project Veritas:

Project Veritas completely exposed the FDA for illegally colluding with vaccine makers.

The FDA responded by lying and saying it isn't their employee. pic.twitter.com/bAQg1SrTWb

— Kαƚყ🕊🌻🎨 (@Katy30770035) February 16, 2022

Hopefully as these snags dissolve, Immunopass will finally get its EUA.

The DED line will certainly make Axim profitable by end of year.

An EUA for Immunopass would undoubtedly put Axim over the top.

The cancer line products are still a few years down the road.